StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $1.90 | $1.94 | +2.11% | 0.9M |
| 05-11 | $1.97 | $2.03 | +3.05% | 1.9M |
| 05-12 | $2.04 | $2.03 | -0.49% | 1.8M |
| 05-13 | $2.03 | $2.12 | +4.43% | 1.7M |
| 05-14 | $2.13 | $2.14 | +0.47% | 3.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for CRBU.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for CRBU.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.40M | $11.16M | $7.22M | $5.02M |
Operating Income | $-26.28M | $-148.34M | $-119.89M | $-90.49M |
Net Income | $-25.09M | $-148.13M | $-121.64M | $-54.10M |
EPS (Diluted) | $-0.26 | $-1.59 | $-1.31 | $-1.01 |
Total Assets | $149.00M | $175.37M | $194.98M | $220.90M |
Total Liabilities | $46.98M | $53.19M | $53.14M | $54.77M |
Cash & Equivalents | $12.06M | $12.36M | $11.14M | $25.20M |
Free Cash Flow OCF − CapEx | $-27.06M | $-112.35M | $-91.74M | $-66.44M |
Shares Outstanding | 96.95M | 95.14M | 93.47M | 93.12M |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.